What is BCYC's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.24B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for BCYC?

P/E (TTM) is n/a and 52-week range is $3.33 to $9.08 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s BCYC figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for BCYC?

The company profile lists revenue (TTM) near $61M, net income (TTM) near -$19.04B, EPS (TTM) near -$2.74 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Bicycle Therapeutics PLC based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Cambridgeshire, GB, 69.8M shares outstanding, ISIN US0887861088 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Bicycle Therapeutics PLC

$BCYC

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Bicycle Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The company is headquartered in Cambridge, Cambridgeshire and currently employs 288 full-time employees. The company went IPO on 2019-05-23. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The firm is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Employees

288

Website

www.bicycletherapeutics.com/

IPO

2019-05-23

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)